Press Releases

The Thermo Scientific 1500 Series Biological Safety Cabinet (BSC) combines safety, energy efficiency and user convenience for today’s modern laboratory. The cabinet offers a high level of personal and product protection from biological hazards and contamination, ease of use with an intuitive touchscreen display and eco-friendly LED lighting for a brighter work environment. The 1500 Series BSC is the latest addition to Thermo Fisher Scientific’s innovative Class II BSC po

ENDRA Life Sciences Inc., a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces an update to its plan to submit a De Novo request for the TAEUS system to the U.S. Food and Drug Administration (FDA). “I’m pleased to announce that preparation of the De Novo documentation by the end of the third quarter is substantially complete,” said ENDRA's Chairman and Chief Executive Officer Francois Michelon. “Our remaining e

Astrea Bioseparations, a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology. Incorporating AstreAdept™, the Company’s proprietary nanofiber material, this novel solution addresses the challenges associated with purifying the large and fragile products used in cell and gene therapy. &l

AION Labs, the first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the formation of OMEC.AI, the lab's first startup approved by the Israel Innovation Authority. The new company will develop AI-powered solutions to analyze pre-clinical data and identify gaps in efficacy and safety to improve the probability of success of drug candidates in clinical trials. OMEC.AI aims to build a

Veeva Systems announced two new Veeva Crossix solutions to help life sciences companies execute and optimize omnichannel marketing campaigns. Veeva Crossix HCP Trigger Data connects consumers' engagement with a brand's website to their healthcare professional (HCP) visits. Veeva Crossix Omnichannel Boost provides a holistic view of HCP and patient engagement across field and promotional channels. Marketing and field teams can now leverage these new offerings for more compreh

A new ultra-compact sterile connector provides biopharmaceutical and cell and gene therapy manufacturers a much-needed alternative to tube welding for their small-volume closed aseptic processes. MicroCNX® Series Connectors are the newest addition to the suite of aseptic connection solutions from CPC, including AseptiQuik® Connectors. The new product is designed to provide a

Eisai Co., Ltd. and Biogen Inc., announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Lecanemab met the primary endpoint (CDR-SB: Clinica

Eagle Pharmaceuticals, Inc., and Enalare Therapeutics Inc., announced that Enalare has secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services (contract number 75A50122C00072). In partnership with BARDA, ENA-001 is being developed in an intramuscular (“IM”) formulation for potential use in p

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the first patient in the global pivotal EFZO-FIT™ study. The Phase 3 study will evaluate the efficacy and safety of the company’s lead therapeutic candidate, efzofitimod, compared to placebo in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, and SynerK, a leading RNAi therapeutics discovery and development company, announced today that they have entered into a research partnership to jointly discover and develop new therapeutics based on small interfering RNA (siRNA) technology to treat liver and metabolic diseases marked by unmet medical needs. This partnership will brin